Northpointe Capital’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q3
$1.23M Sell
10,955
-13,043
-54% -$1.45M 0.47% 76
2019
Q2
$2.66M Buy
23,998
+7,744
+48% +$912K 0.84% 60
2019
Q1
$2.11M Buy
+16,254
New +$1.98M 0.66% 69
2015
Q2
Sell
-56,611
Closed -$4.11M 215
2015
Q1
$4.11M Buy
56,611
+11,655
+26% +$830K 0.45% 72
2014
Q4
$3.1M Buy
+44,956
New +$3.03M 0.37% 89
2013
Q4
Sell
-29,317
Closed -$1.48M 248
2013
Q3
$1.48M Buy
29,317
+17,397
+146% +$911K 0.17% 134
2013
Q2
$586K Buy
+11,920
New +$649K 0.07% 170

Other funds holding LLY

Northpointe Capital's LLY Position: Q3 2019 in Review

Northpointe Capital reduced its Eli Lilly (LLY) stake by 54% in Q3 2019, selling an estimated $1.45M and leaving 10,955 shares worth $1.23M. The position accounts for 0.47% of the portfolio, ranked #76.

Northpointe Capital first reported a position in LLY in Q2 2013 and has held it in 7 quarters since. The position peaked at $4.11M in Q1 2015. 1,525 funds tracked by Wall St. Rank hold LLY as of Q3 2019.

  • Northpointe Capital held 10,955 shares of Eli Lilly worth $1.23M as of Q3 2019.
  • Northpointe Capital sold 13,043 Eli Lilly shares in Q3 2019, an estimated $1.45M.
  • Eli Lilly made up 0.47% of Northpointe Capital's portfolio in Q3 2019, its #76 holding.
  • Northpointe Capital first reported a position in Eli Lilly in Q2 2013 and has held it in 7 quarters since.
  • Northpointe Capital's Eli Lilly position peaked at $4.11M in Q1 2015.
  • 1,525 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2019.

Based on Northpointe Capital's 13F filing for Q3 2019, filed 16 Oct 2019.